Pharma BD Deal Intelligence

Amicus Therapeutics, Inc. / Dimerix Limited

2025 · Licensing/Option · $590M · Complete

Amicus Therapeutics licensed exclusive U.S. commercialization rights to Dimerix's Phase 3 candidate DMX-200 for all indications, including focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies. Dimerix receives a US$30 million upfront payment and is eligible for up to US$560 million in success-based milestone payments plus tiered royalties on U.S. net sales. Dimerix retains rights in all territories not already exclusively licensed. DMX-200 is a CCR2 inhibitor in the pivotal ACTION3 study; Dimerix completed a Type C meeting with FDA in March 2025 aligning on proteinuria as the primary approval endpoint.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals